When Dr. Ed Kaye was the CEO of Sarepta Therapeutics, he steered the company through a controversial approval process for its drug to treat Duchenne muscular dystrophy. The drug, Exondys 51, won approval based on a trial in only 12 patients, against the advice of a Food and Drug Administration panel and amid strong lobbying by families affected by Duchenne muscular dystrophy.

That decision in 2016 has helped shape FDA policy for rare diseases ever since. Kaye, who’d been Sarepta’s chief medical officer for six years before stepping into the CEO role for nine months, left the company in 2017. 

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy